🔗 Share this article

An high-ranking health official has been recused from oversight in an major research project concerning hormone suppressants after claims of partiality emerged.

Alleged Intervention Resulted in Study Halt

According to media accounts, Professor Jacob George, a chief medical director at the regulatory agency, voiced worries which resulted in the suspension of the government-backed research initiative during February.

The authority announced on Saturday that the professor had recused him from any role in the trial after gender-critical social media posts posted previously emerged.

Nature of Social Media Comments

In a post, he described author the Harry Potter author as a “treasure of our time.” Separately, he remarked how “the denial to accept fundamental biological fact is concerning” in relation to discussions over an Olympic boxer’s sex.

The agency stated that although the comments were posted before the role began, he had been taken off of oversight with the trial as an preventative measure.

Particulars of the Halted Pathways Study

This research project, that was designed to study the impact from hormone suppressants for adolescents questioning their gender identity, was set to commence enrolling volunteers in January.

But, the trial was halted in February when the agency voiced worries regarding the welfare of young participants taking part.

• The most junior participants were projected to be 10 to 11 for girls while 11 to 12 among boys.
• Its trial leadership said earlier how the strict screening procedure suggested participants would probably be of a higher age.
• However, officials have since stated the minimum age limit must be fourteen because of the uncertain potential” for “long-term health consequences.”

This research was designed to include around 226 adolescents during the coming three years.

Context Following the Independent Report

This study was commissioned following a recommendation from the Cass review into children’s gender identity services, that found that the standard of the research claiming to prove the advantages from this type of drugs in youngsters with gender incongruence was low-quality.”

Dr Hilary Cass, who led the review, has previously stated her report exposed a very weak evidence base” supporting the benefits of puberty blockers.

She continued, considering that there are clinicians, children and families who believe strongly in the helpful results, research was the sole method forward to make sense of this.”

Medical Concern Regarding the Action

Dr Max Davie, an expert in adolescent medicine, said there existed no convincing evidence-based justification to suspend the trial.

“The online comments by Prof George give an obvious insight of his individual stance regarding gender identity,” he said. “He is entitled to hold whatever views on this subject he wishes, but what he cannot do is allow these views to affect the execution of his public duty.”

He continued: “To be clear, there is no persuasive scientific reason to halt the Pathways trial. While the professor’s own views are not the sole potential reason of the regulator’s abrupt change of position, it are the single factor for which evidence.”

Agency Statement Regarding Future Actions

A MHRA representative commented: “In every clinical trials, our foremost duty is the protection as well as welfare for the trial participants. As part of this duty, detailed clinical trials are kept continuously under scrutiny while the agency keeps a continuous discussion alongside study funders.”

“We have expert scientific, medical and oversight professionals who work as a collaborative group to provide evidence-based judgments regarding clinical trials. These experts are continuing to work alongside the research team to work through the next steps in a positive manner.”

“After the identification regarding social media activity made prior to he took up his role, Prof Jacob George is recused of continued involvement regarding the Pathways study as a precaution.”